New hope for kids with severe asthma: drug aims to cut attacks

NCT ID NCT05692180

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This study tests whether benralizumab, an injected drug, can reduce asthma attacks in children aged 6 to 17 with severe eosinophilic asthma. About 200 participants will receive either benralizumab or a placebo, and researchers will track how long it takes for their first asthma flare-up to occur. The goal is to see if this treatment can help kids whose asthma is not well controlled with current medications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: benralizumab
What this could lead to: If it works, this could give children with severe asthma a new treatment option that reduces flare-ups and improves daily symptoms.
What could go wrong: This is a Phase 3 trial, but results may not apply to all children. Benralizumab is already approved for adults, but its safety and effectiveness in kids are still being confirmed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma pulmonary eosinophilia T2-high asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA

Contacts and locations

Locations

Research Site

Torrance, California, 90505, United States
Research Site

Ocala, Florida, 34471, United States
Research Site

Owensboro, Kentucky, 42301, United States
Research Site

Lafayette, Louisiana, 70508, United States
Research Site

Kansas City, Missouri, 64108, United States
Research Site

Northfield, New Jersey, 08225, United States
Research Site

The Bronx, New York, 10459, United States
Research Site

Cincinnati, Ohio, 45229, United States
Research Site

Charleston, South Carolina, 29425, United States
Research Site

San Antonio, Texas, 78229, United States
Research Site

Tyler, Texas, 75708, United States
Research Site

Ciudad de Buenos Aires, C1414AIF, Argentina
Research Site

Ciudad de Buenos Aire, C1425DTG, Argentina
Research Site

Florida, B1602DQD, Argentina
Research Site

Lobos, 7240, Argentina
Research Site

Mar del Plata, B7600, Argentina
Research Site

Mendoza, 5500, Argentina
Research Site

Mendoza, M5500CCG, Argentina
Research Site

Rosario, 2000, Argentina
Research Site

San Juan Bautista, 1888, Argentina
Research Site

Santa Fe, S3000ASF, Argentina
Research Site

Créteil, 94010, France
Research Site

Lyon, 69394, France
Research Site

Rouen, 76031, France
Research Site

Milan, 20142, Italy
Research Site

Roma, 00165, Italy
Research Site

Bialystok, 15-879, Poland
Research Site

Krakow, 31-624, Poland
Research Site

Lodz, 90-302, Poland
Research Site

Skarżysko-Kamienna, 26-110, Poland
Research Site

Tarnów, 33-100, Poland
Research Site

Cheongju-si, 28644, South Korea
Research Site

Junggu, 22332, South Korea
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Badalona, 08916, Spain
Research Site

Barcelona, 8035, Spain
Research Site

Benalmádena, 29631, Spain
Research Site

Esplugues de Llobregat, 8950, Spain
Research Site

Kaohsiung City, 833, Taiwan
Research Site

Taoyuan, 333, Taiwan
Research Site

London, SE5 9RS, United Kingdom
Research Site

Manchester, M13 9PL, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.